The present study tested the possibility that pharmacological treatment with the brain penetrant FRAX486,25, 26 a small synthetic molecule that was reported to selectively inhibit PAKs,25 might rescue CDD‐related neurobehavioral alterations in a Cdkl5‐KO mouse model. This evidence concerns the gene CDKL5 and craniodiaphyseal dysplasia.